{
    "title": "115_hr5687",
    "content": "The Act is named the \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act.\" It introduces safety-enhancing packaging and disposal features for certain drugs. The Secretary may issue orders requiring the implementation of technologies to mitigate drug abuse risks for specific drugs listed in a covered application. Prior consultation with stakeholders is required, and measures must be proportionate to the abuse risk of the drug. The Secretary may issue orders to implement technologies to reduce drug abuse risks for specific drugs listed in a covered application. The orders must not overly restrict patient access and should aim to decrease the risk of drug abuse or misuse. The orders can include various options for implementing required technologies and may reference packaging or disposal standards from recognized organizations. The Food and Drug Administration may issue orders to address drug abuse risks for specific drug classes, requiring holders of covered applications to submit proposed changes within a specified timeframe. Compliance with the orders is mandatory to mitigate the risk of abuse or misuse. The FDA may issue orders for drug abuse risks, requiring changes to be implemented within 90 days or a longer period approved by the Secretary. Holders of covered applications can propose alternative measures for approval. The FDA may approve alternative technologies, controls, or measures for drug packaging, storage, or disposal if they can mitigate abuse or misuse risks to the same extent as specified measures in an order. Disputes regarding submitted supplements can be appealed using specified dispute resolution procedures. The FDA may approve alternative technologies, controls, or measures for drug packaging, storage, or disposal to mitigate abuse or misuse risks. Relevant stakeholders include various industry experts, healthcare providers, and government agencies. Prohibited acts under the Federal Food, Drug, and Cosmetic Act are outlined, with procedures for dispute resolution. The FDA may approve alternative technologies, controls, or measures for drug packaging, storage, or disposal to mitigate abuse or misuse risks, including opioids listed under the Controlled Substances Act. The FDA may approve alternative technologies, controls, or measures for drug packaging, storage, or disposal to mitigate abuse or misuse risks, including opioids listed under the Controlled Substances Act. Refusal to approve an Abbreviated New Drug Application may occur if the applicant fails to propose adequate technologies, controls, or measures related to packaging or disposal that provide comparable protections to those required for the applicable listed drug. The FDA may approve alternative technologies, controls, or measures for drug packaging, storage, or disposal to mitigate abuse or misuse risks. Any labeling related to packaging or disposal for a drug subject to an abbreviated new drug application should not be seen as changes to labeling not permissible under the Act or preclude approval of the application. The FDA may approve alternative technologies, controls, or measures for drug packaging, storage, or disposal to mitigate abuse or misuse risks. Any labeling related to packaging or disposal for a drug subject to an abbreviated new drug application should not be seen as changes to labeling not permissible under the Act or preclude approval of the application. Subsection (j) of section 505 of the Federal Food, Drug, and Cosmetic Act does not limit the type of data the Secretary of Health and Human Services may consider. The Comptroller General of the United States will submit a report to Congress within 12 months on the effectiveness of in-home controlled substance disposal products and barriers to their use by patients and consumers. The curr_chunk describes Federal oversight of site-of-use and in-home controlled substance disposal products, including identification of overseeing agencies, recommended disposal methods, and effectiveness in preventing diversion of controlled substances. It also discusses Federal oversight of controlled substance packaging technologies, identifying overseeing agencies and recommended technologies such as unit dose packaging. The curr_chunk provides recommendations on Federal oversight of in-home controlled substance disposal products and packaging technologies, including agency responsibilities and product efficacy evaluation. The curr_chunk states that the document was passed by the House of Representatives on June 19, 2018, with Karen L. Haas as the Clerk."
}